TapImmune Inc. (OTCBB: TPIM)

Dear Reader,

TapImmune Inc. (OTCBB: TPIM) released a major shareholder update outlining the progress in the validation of the company's technology, supported by no less than nine peer-reviewed scientific journal publications. The data was generated through its collaborative research with The UBC and subsequently published by the worlds leading journals.  This growing body of validation will surely boost the confidence of TapImmune scientists as they endeavor to bring a novel and effective treatment for many types of cancer to the market.  TapImmune also indicated that it expects initiate the move from proof of concept into the clinical arena very shortly.  

Breaking *NEWS* From TapImmune

VANCOUVER, British Columbia, Aug. 1, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTC BB:TPIM.OB - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders.

The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia and signifies the start of the pre-clinical process to commercialize its core TAP technologies.

The past year has seen some excellent progress in the validation of the company's technology, supported by no less than nine peer-reviewed scientific journal publications. One of those studies, published in Cancer Research, showed that a wide variety of human carcinomas have low expression of tumor-associated antigen presentation (TAP) and concluded that the company's method of reintroducing TAP should be considered as a part of the immunotherapy for various cancers. This study, titled ``Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival,'' showed that the company's technology is likely to provide a general method for increasing immune responses against tumors regardless of the antigenic composition of the tumor.

In a separate study titled ``Anti-Tumor Immunity and T Cell Memory are Induced by Low Dose Inoculation with Nonreplicating Recombinant Adenovirus Encoding TAP1,'' published in Science Direct: Vaccine: 25 (2331-2339) 2007, the manuscript makes several exciting and novel observations. The results suggest that the inclusion of TAP in vaccines for cancer may promote and maintain long-term anti-tumor responses even when the vector used to deliver TAP only infects a small fraction of the metastatic tumor cells. This novel approach uses a small amount of vaccine relative to the tumor size, and thus achieves an efficacious outcome that has so far eluded other vaccine, immunotherapeutic or gene therapeutic strategies. The experiments are well controlled and clearly described, and the conclusions are supported by the experimental data presented.

A similar study using the Vaccinia virus and TAP showed equally promising results in melanoma.

"All of the data generated from our collaborative research with the UBC and subsequently published by the worlds leading journals has given us confidence that we are on the right track to bring a novel and effective treatment for many types of cancer to the market," said Denis Corin, CEO of TapImmune Inc. "With this kind of data behind us we are excited to now be at a stage where we can move this proof of concept into the clinical arena. We expect to announce the initiation of that process very shortly."

Abstracts of all the studies are available on the company website and are linked to their respective journals.

About TapImmune Inc.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The companies' lead product, the AdhTAP vaccine enhancer restores and augments antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of a Phase I clinical trial. The company is also developing a TAP-based vaccine adjuvant already proven to increase the efficacy of targeted prophylactic vaccines by up to 1,000 times.

The TapImmune Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3877

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are ``forward-looking statements''. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at http://www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

Contact:

         TapImmune Inc.
         Denis Corin, CEO
         604-264-8274
         info@TapImmune.com 
         www.TapImmune.com
>>>a

About TapImmune

a

TapImmune Inc. ("TapImmune" "TPIM") is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. TPIM technologies are based on an understanding of the function of a protein "pump" within cells that is essential in the processing of tumor antigens, known as TAP. Transporters Associated with Antigen Processing (TAP) are transporters responsible for supplying tumor-associated antigens and viral antigens used in the assembly of MHC class I surface molecules. MHC class I molecules are required for the recognition and destruction of tumor cells and virus infected cells by the cellular arm of the immune system. A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable by the immune system. 

TPIM's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells allowing the subsequent recognition and killing of cancer cells by the immune system.. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. 

TPIM's vaccine has shown effective restoration of TAP and the TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the much studied Smallpox Vaccine, its potency was increased by 100-1000 times. TPIM is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. 

TapImmune Inc. was previously known as Genemax and on March 18, 2003, a production service agreement with Molecular Medicine BioServices, Inc., was entered into that called for the production of its clinical vector for delivery of the Transporters Associated with Antigen Processing genes. On February 16, 2004, TPIM scientists added to the company technology portfolio by expanding the license with the University of British Columbia, to include a technological method that identifies novel, tumor-associated antigens produced by cancers. On October 21, 2003, TPIM scientists entered into a Biological Materials Transfer Agreement with the National Institute of Allergy and Infectious Diseases in Canada . 

• Conduct preclinical vaccine programs and move successes through to human trials 
• Discover, acquire and develop technologies that modulate antigen presentation 
• Commercialize proprietary products through corporate alliances 
• Develop business partnerships that enhance the efficacy of other immunotherapeutic and vaccine products 

Traditional approaches to cancer treatments have included surgery, radiation therapy and chemotherapy. Because of the difficulty in removing or destroying all cancer cells, these approaches leave a high mortality rate and numerous side effects for many cancers. TapImmune’s alternative to the traditional approaches to cancer treatment is based on increased knowledge of the human genome and immune system. The TAP technology approach holds the potential of higher efficacy and lower side effects in cancer treatment and for protection to infectious diseases.

Clinical studies to date have identified a large number of cancers deficient in TAP including but not limited to HPV related cancers such as melanoma, lung, prostate, breast and ovarian cancer. TapImmune believes these tumors would be responsive to the TAP therapeutic vaccine. In preclinical trials for melanoma and lung carcinoma, animal survival rates of 70% were achieved using TAP vaccine therapy and 100% survival when TAP was administered ex-vivo. 

The current estimates for cancer treatments such as chemotherapy represent approximately a $10 billion market. Cancer vaccines will become a major player in the vaccine market rising from current levels of $135 million to more than $8 billion by 2012. (Washington UPI – Feb 2007)

Prophylactic vaccines require the use of adjuvants to generate adequate protective immunity to prevent or treat diseases. As a result, most vaccines are combined with an adjuvant that enhances the ability of an injected vaccine to stimulate an immune response and thus protect the recipient by preventing or treating diseases. TapImmune’s vaccine adjuvant has shown 100 times greater potency than non-adjuvanted vaccines in animal studies when combined with vaccines.

Currently, there is only one FDA-approved adjuvant available for use in humans. The need to immunize entire populations against a growing number of infectious diseases will require greater efficiency of the primary vaccine inoculae. a
a

TapImmune in the Media and TPIM Press Releases

Press Release Source: WallStreet Direct, Inc. 
Friday July 6, 7:00 am ET 

NEW YORK, July 6 /PRNewswire/ -- On July 3, Denis Corin, Chief Executive Officer of TapImmune, Inc. (OTC Bulletin Board: TPIM - News) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones investors should watch for. To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

You may view the entire release HERE

VANCOUVER, British Columbia, June 28, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTC BB:TPIM.OB - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key Transporter Associated with Antigen Processing (TAP) technology platform and patents. All financial terms with The University of British Columbia have been met. Technology assignment and transfer is expected to be completed in the next week.

The Company (previously GeneMax Corp) had been operating under an exclusive world-wide license from The University of British Columbia (UBC) for the use of TAP as an immunotherapy in the treatment of a broad spectrum of metastatic cancers deficient in this molecule. Initial animal studies have shown that restoring TAP can significantly improve outcomes and survival by up to 70%. This technology was discovered by Dr. Wilf Jefferies, a world expert in and professor of Immunology and Microbiology at the Michael Smith Laboratories at The UBC.

In addition, the use of TAP as a molecular adjuvant for reviving and optimizing vaccines against infectious disease was also discovered. This exciting discovery has far reaching potential applications in fighting and eradicating viral diseases in humans and many additional veterinary applications. The initial proof of concept studies showed a 100 to 1000 fold increase in the potency of a targeted vaccine.

"This acquisition is a milestone achievement for the company and essentially results in the birth of a new independent entity. I believe it will give our shareholders significant value going forward and firmly places our destiny in our own hands," said Denis Corin, recently appointed President and CEO. "This past year has been strategically important for the company. We have had to do some restructuring and have refocused our development programs to move our technology from the lab to the clinic and have positioned us very well to enter the $13 billion world wide vaccine market."

You may view the entire release HERE
a

The Management and Directors of TPIM

Management and Directors

Alan P. Lindsay
Director and Chairman of the Board
Alan Lindsay has extensive experience in building companies and taking them public on recognized stock exchanges.  He is currently Chairman, President and CEO of MIV Therapeutics, Inc. (MIVT-OB).  Before coming to MIVT, Mr Lindsay was the Chairman, President and CEO of Azco Mining Inc. listed on the TSX and AMEX.  He was also the Chairman of GeneMax Pharmaceuticals Inc., the predecessor non-reporting company, which he co-founded in 1999 and assisted with financing prior to leaving the company in 2001.  Prior to this, Mr. Lindsay was responsible for building a significant business and marketing organization in Vancouver, Canada, for Manulife Financial, a major international financial services corporation.

Denis D Corin
President, Chief Executive Officer
Denis Corin is a management consultant with experience in large pharmaceutical (Novartis), diagnostic instrumentation companies (Beckman Coulter) as well as the small cap biotech arena (MIV Therapeutics). He holds a double major, Bachelors degree in Economics and Marketing from the University of Natal, South Africa.

Dr. Wilfred Jefferies, D.Phil.
Principle Scientist
Dr. Jefferies oversees technical development at TapImmune.  He previously founded Synapse Technologies Inc., subsequently acquired by Biomarin Pharmaceuticals Inc.  A world expert in understanding immune responses against pathogens and tumors, he is the lead researcher and inventor of GeneMax’s scientific technologies.  Dr. Jefferies holds a BSc in biochemistry from the University of Victoria and a DPhil degree in molecular immunology from Oxford University.

Patrick A. McGowan
Secretary, Chief Financial Officer and Principal Accounting Officer
Patrick McGowan is a management consultant specializing in assisting public companies with financing, regulatory filings, administration and business plans.  He is currently the CFO of MIV Therapeutics, Inc. (MIVT-OB) where he is responsible for negotiations with attorneys, auditors and financial institutions, and the day to day business operations of MIVT.  Previously he served as CEO of American Petro-Hunter, Inc.  Mr. McGowan obtained his Masters of Business Administration from the University of Western Ontario and his Bachelors of Science from the University of Oregon.

Glynn Wilson, Ph.D.
Director
Dr. Wilson was President of Auriga Laboratories, Inc. which develops pharmaceutical products based on patented drug delivery technologies.  He has held a number of high-profile senior management positions in global pharmaceutical organizations and start-up drug delivery companies.

He is a recognized leader in the development of drug delivery systems with extensive experience in such technologies.  Dr. Wilson was Worldwide Leader of Drug Delivery at SmithKline Beecham Pharmaceuticals where he was involved in the development of products involving new drug delivery systems.  In addition, he was a founding member of the Advanced Drug Delivery Group at Ciba-Geigy. 

As Executive Vice President for Research and Development at Tacora Corporation, he was responsible for conceiving and developing lead products and providing leadership in the merging of Tacora Corporation with Access Pharmaceuticals.

Scientific Advisors

Dr. Terry Pearson is a professor of Biochemistry and Microbiology at the University of Victoria. His current research involves development of new diagnostic methods using the human plasma proteome and mass spectrometry.  Dr. Pearson was involved with the early stages of development of monoclonal antibodies in Cambridge, England and takes a particular interest in alternate methods for their derivation, production and use in immunodiagnostics and in vaccine development.
a

Financial Highlights For  TapImmune Inc.

TO CONTACT TPIM

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid one hundred thousand restricted common shares of TPIM and ten thousand dollars/U.S. by TapImmune Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.